About Us

About us

Our Mission

innoVitro is a biotech company with core competence in the measurement of cellular forces, in particular of stem cell derived cardiomyocytes.

Cardiovascular diseases are the most common cause of death in the western world. Although mortality is steadily decreasing due to the continuous improvement of emergency medical care, late effects lead to a loss of life quality and high follow-up costs for the health care system. These late effects can be treated by medications with a strength-enhancing effect, which can significantly improve the quality of life of those affected. In the development and characterization of these drugs, the pharmaceutical industry has been dependent on animal experiments, which not only cost a great deal of money but also raise ethical concerns among public opinion.

innoVitro is working on the establishment of an in vitro cardiac muscle model based on the FLEXcyte technology and human cardiac muscle cells.

The model is intended to be an alternative to animal experiments which will enable the qualitative and quantitative determination of substance effects on the contractility of myocardial cells. By using human stem cell derived cardiomyocytes, common issues with the translatability of pharmacological results from animal models to human physiology are avoided already in the preclinical phase of drug development.

Our Team

Peter Linder and Dr. Matthias Goßmann – Founders of innoVitro

Dr. rer. nat. Dipl. Ing. (FH) Matthias Goßmann holds a degree in biotechnology and a doctorate in chemistry. Since 2008, he has been working on the development of the CellDrum technology. He gained 3.5 years of experience as a scientist in stem cell industry (Axiogenesis AG) before turning to the field of business development as one of the two founders of innoVitro.

The second founder of innoVitro, Dipl. Ing. (FH) Peter Linder MSc., has already contributed to the first development steps of the CellDrum technology, the predecessor of the FLEXcyte, in his diploma thesis in the field of biomedical technology. His further career includes a Master of Science in cooperation with the University Hospital of Cologne as well as project work in the field of aerospace technology. Besides his current doctorate on III. Physical Institute B at RWTH Aachen University, he is responsible at innoVitro for hardware and software development as well as laboratory management.

The team has been working together successfully for many years and complements each other excellently in its personal and professional qualities.

Dr. Bettina Lickiss

Since 2019 Dr. rer. nat. Dipl. Biol. Bettina Lickiss is the third member of the innoVitro team and responsible for marketing solutions and business development. Bettina holds a doctorate degree in neurobiology and gained 5 years of experience in the stem cell biotech industry and field of human iPSC-derived cardiomyocytes before working for innoVitro.

Our Partners

Nanion Technologies is one of the world’s leading providers of cell-based assays, from automated patch clamp to extracellular recording techniques. The decision to collaborate was made in 2018 in order to develop a 96 well screening system to measure and analyse cardiac contractility based on the “CellDrum” technology. The CellDrum was originally co-developed by Dr. Matthias Gossmann and Peter Linder at the Biophysical Laboratory of Biomedical Engineering of the University of Applied Science Aachen.

The outcome of this partnership is the FLEXcyte 96, an add-on system for the CardioExcyte 96, that works as a bench top incubation system to be independent from a typical incubator. A unique data handling software package comes along with the FLEXcte 96 to ensure maximum outcome of the acquired data. Nanion Technologies is responsible for the production and distribution of the FLEXcyte 96 device in close cooperation with innoVitro. Services carried out with the FLEXcyte 96 are performed by innoVitro.

innoVitro and Nanion Technologies complement each other by permanent support regarding each other’s FLEXcyte related research & development as well as customer support.


The team of innoVitro is a member of the HESI Cardiac Safety Technical Committee, a consortium of pharmaceutical companies, technology providers, regulatory authorities and universities where new technologies are evaluated.

The HESI Commitee’s mission is to improve public health by reducing unexpected cardiovascular-related side effects from drugs or chemicals by developing innovative approaches to support early detection and prediction of cardiovascular toxicology and pathobiology.

"The FLEXcyte brings another dimension to iPS-derived cardiomyocyte based assays. Measuring contractility in such a direct and easy way allows us to understand the cell functionality better and will help us in both our product development and safety pharmacology research"

Choong-seong (Henry) Han,
CEO, Founder, D.D.S., Ph.D.,
NEXEL Co., Ltd.